<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1-363-04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2004
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        REBIF 44 MCG PRE-FILLED SYRINGE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        INTERFERON BETA-1A
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        44
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        IU
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        0
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        12
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        3968.2
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SERONO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SERONO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SERONO
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L03AB07
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Rebif belongs to a class of medicines known as interferons. These are natural substances that transmit messages between cells. Interferons are produced by the body and play an essential role in the immune system. Through mechanisms that are not totally understood, interferons help to limit the damage of the central nervous system associated with multiple sclerosis.</p><p dir="ltr">Rebif is a highly purified soluble protein that is similar to the natural interferon&nbsp;beta that is produced in the human body.</p><p dir="ltr">Rebif<strong><em> </em></strong>is used for the treatment of multiple sclerosis. It has been shown to reduce the number and the severity of relapses and to slow the progression of disability. It is also approved for use in patients who have experienced a single clinical event likely to be a first sign of multiple sclerosis.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Do not use Rebif</strong></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to natural or recombinant interferon&nbsp;beta or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are pregnant (see Pregnancy and breast-feeding).</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are severely depressed at present.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Warnings and precautions</strong></p><p dir="ltr">Talk to your doctor, pharmacist or nurse before using Rebif.</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rebif should only be used under the supervision of your doctor.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Before treatment with Rebif, read carefully and follow the advice given under &ldquo;How to use Rebif&rdquo; in order to minimise the risk of injection site necrosis (skin breakdown and tissue destruction) that has been reported in patients treated with Rebif. If you experience troubling local reactions, contact your doctor.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Talk to your doctor or pharmacist before taking Rebif if you have an allergy (hypersensitivity) to any other medicines.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood clots in the small blood vessels may occur during your treatment. These blood clots could affect your kidneys. This might happen several weeks to <u>several years</u> after starting Rebif. Your doctor may want to check your blood pressure, blood (platelet count) and the function of your kidney.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Inform your doctor if you have a disease of</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the bone marrow,</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kidney,</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver,</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart,</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thyroid,</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; or if you have experienced depression,</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; or if you have any history of epileptic seizures,</p><p dir="ltr">so that he/she can closely monitor your treatment and any worsening of these conditions.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Other medicines and Rebif</strong></p><p dir="ltr">Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines.</p><p dir="ltr">In particular you should tell your doctor if you are using antiepileptics or antidepressants.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Pregnancy and breast‑feeding</strong></p><p dir="ltr">If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p dir="ltr">&nbsp;</p><p dir="ltr">You must not start treatment with Rebif&nbsp;if you are pregnant. While taking Rebif, you must use effective methods of contraception if you are a woman of child‑bearing potential. If you become pregnant or plan to become pregnant while using Rebif ask your doctor for advice.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Prior to taking the medicine, please inform your doctor if you are breast‑feeding. The use of Rebif is not recommended if you are breast‑feeding.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Driving and using machines</strong></p><p dir="ltr">Effects of the disease itself or of its treatment might influence your ability to drive or to use machines. You should discuss this with your doctor if you are concerned.</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>Rebif contains benzyl alcohol</strong></p><p dir="ltr">Rebif contains 2.5&nbsp;mg benzyl alcohol per dose. It must not be given to premature babies or neonates. It may cause toxic reactions and allergic reactions in infants and children up to 3 years old.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr">Always use this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>Dose</strong></p><p dir="ltr"><em>Patients who have experienced a single clinical event </em></p><p dir="ltr">The usual dose is 44&nbsp;micrograms (12&nbsp;million&nbsp;IU) given three&nbsp;times per&nbsp;week.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Patients with multiple sclerosis</em></p><p dir="ltr">The usual dose is 44&nbsp;micrograms (12&nbsp;million&nbsp;IU) given three&nbsp;times per&nbsp;week.</p><p dir="ltr">&nbsp;</p><p dir="ltr">A lower dose of&nbsp;22&nbsp;micrograms (6 million IU) given three&nbsp;times per&nbsp;week is recommended for patients who cannot tolerate the higher dose.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Rebif should be administered three times per week, and if possible:</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; on the same three&nbsp;days every week (at least 48&nbsp;hours apart, e.g. Monday, Wednesday, Friday)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; at the same time of day (preferably in the evening).</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>Use in children and teenagers (2 to 17&nbsp;years old)</strong></p><p dir="ltr">No formal clinical studies have been conducted in children or teenagers. However, there is some clinical data available suggesting that the safety profile in children and teenagers receiving Rebif 22&nbsp;micrograms or Rebif 44&nbsp;micrograms three times per week is similar to that seen in adults.&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Use in children (below 2&nbsp;years of age)</strong></p><p dir="ltr">Rebif is not recommended for use in children below 2&nbsp;years of age.</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>Method of administration</strong></p><p dir="ltr">Rebif is intended for subcutaneous (under the skin) injection.</p><p dir="ltr">The first injection(s) must be performed under the supervision of an appropriately qualified healthcare professional. After receiving adequate training, you, a family member, friend or carer can use Rebif syringes to administer the medicine at home. It may also be administered with a suitable auto-injector.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>For administration of Rebif, please read the following instructions carefully:</strong></p><p dir="ltr">This medicine is for single use. Only clear to opalescent solution without particles and without visible signs of deterioration should be used.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>How to inject Rebif</em></p><p dir="ltr"><em>&nbsp;</em></p><table border="0" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
   o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
   stroked="f">
   <v:stroke joinstyle="miter"/>
   <v:formulas>
    <v:f eqn="if lineDrawn pixelLineWidth 0"/>
    <v:f eqn="sum @0 1 0"/>
    <v:f eqn="sum 0 0 @1"/>
    <v:f eqn="prod @2 1 2"/>
    <v:f eqn="prod @3 21600 pixelWidth"/>
    <v:f eqn="prod @3 21600 pixelHeight"/>
    <v:f eqn="sum @0 0 1"/>
    <v:f eqn="prod @6 1 2"/>
    <v:f eqn="prod @7 21600 pixelWidth"/>
    <v:f eqn="sum @8 21600 0"/>
    <v:f eqn="prod @7 21600 pixelHeight"/>
    <v:f eqn="sum @10 21600 0"/>
   </v:formulas>
   <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
   <o:lock v:ext="edit" aspectratio="t"/>
  </v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75"
   alt="injection" style='width:60pt;height:117.75pt;visibility:visible'>
   <v:imagedata src="file:///C:/Users/M272521/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title="injection"/>
  </v:shape><![endif]--><img width="80" height="157" alt="injection" src="file:///C:/Users/M272521/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Choose an injection site. Your doctor will advise you on the possible injection sites (good sites include the upper thighs and the lower abdomen). Hold the syringe like a pencil or dart. It is recommended that you keep track of and rotate your injection sites, so that one area is not injected too frequently in order to minimise the risk of injection site necrosis.</p><p>NOTE: do not use any areas in which you feel lumps, firm knots, or pain; talk to your doctor or healthcare professional about anything you find.</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wash your hands thoroughly with soap and water.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove the Rebif syringe from the blister pack by peeling back the plastic covering.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Before the injection, use an alcohol wipe to clean the skin at the injection site. Let the skin dry. If a bit of alcohol is left on the skin, you may get a stinging sensation.</p><p dir="ltr">&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="Picture_x0020_2" o:spid="_x0000_i1026"
   type="#_x0000_t75" style='width:105pt;height:88.5pt;visibility:visible'>
   <v:imagedata src="file:///C:/Users/M272521/AppData/Local/Temp/msohtmlclip1/01/clip_image003.wmz"
    o:title=""/>
  </v:shape><![endif]--><img width="140" height="118" src="file:///C:/Users/M272521/AppData/Local/Temp/msohtmlclip1/01/clip_image004.png" /></p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gently pinch the skin together around the site (to lift it up a bit).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Resting your wrist on the skin near the site, stick the needle at a right angle straight into the skin with a quick, firm motion.</p></td></tr><tr><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape id="Picture_x0020_3" o:spid="_x0000_i1027"
   type="#_x0000_t75" style='width:105pt;height:104.25pt;visibility:visible'>
   <v:imagedata src="file:///C:/Users/M272521/AppData/Local/Temp/msohtmlclip1/01/clip_image005.wmz"
    o:title=""/>
  </v:shape><![endif]--><img width="140" height="139" src="file:///C:/Users/M272521/AppData/Local/Temp/msohtmlclip1/01/clip_image006.png" /></p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inject the medicine by using a slow, steady push (push the plunger all the way in until the syringe is empty).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hold a swab on the injection site. Remove the needle from the skin.</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gently massage the injection site with a dry cotton ball or gauze.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dispose of all used items: once you have finished your injection, immediately discard the syringe in an appropriate disposal unit.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>If you use more Rebif than you should</strong></p><p dir="ltr">In case of overdose, contact your doctor immediately.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>If you forget to use Rebif</strong></p><p dir="ltr">If you miss a dose, continue to inject from the day of the next scheduled dose. Do not use a double dose to make up for a forgotten dose.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>If you stop using Rebif</strong></p><p dir="ltr">The effects of Rebif may not be noticed immediately. Therefore, you should not stop using Rebif but continue to use it regularly to achieve the desired result. If you are uncertain about the benefits, please consult your doctor.</p><p dir="ltr">&nbsp;</p><p dir="ltr">You should not discontinue the treatment without first contacting your doctor.</p><p dir="ltr">&nbsp;</p><p dir="ltr">If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>Tell your doctor immediately and stop using Rebif if you experience any of the following serious side effects:</strong></p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Serious allergic (hypersensitivity) reactions</strong>. If, immediately following Rebif administration you experience a sudden difficulty breathing, which may appear in association with swelling of face, lips, tongue or throat, nettle rash, itching all over the body, and a feeling of weakness or faintness, contact your doctor immediately or seek urgent medical attention. These reactions are <em>rare</em> (may affect up to 1 in 1,000&nbsp;people).</p><p dir="ltr">&nbsp;</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inform your doctor immediately if you experience any of the following possible symptoms of a <strong>liver problem</strong>: jaundice (yellowing of the skin or of the whites of the eyes), widespread itching, loss of appetite accompanied by nausea and vomiting and easy bruising of the skin. Severe liver problems can be associated with additional signs, e.g. difficulty concentrating, sleepiness and confusion.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Depression</strong> is <em>common</em> (may affect up to 1 in 10&nbsp;people) in treated patients with multiple sclerosis. If you feel <strong>depressed or develop thoughts of suicide</strong>, report it immediately to your doctor.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Talk to your doctor if you experience any of the following side effects:</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Flu-like symptoms,</strong> such as headache, fever, chills, muscle and joint pains, fatigue and nausea are <em>very common </em>(may affect more than 1 in 10&nbsp;people).</p><p dir="ltr">These symptoms are usually mild, are more common at the start of the treatment and decrease with continued use.</p><p dir="ltr">To help reduce these symptoms your doctor may advise you to take a fever reducing painkiller before a dose of Rebif and then for 24&nbsp;hours after each injection.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Injection site reactions</strong> including redness, swelling, discoloration, inflammation, pain and skin breakdown are <em>very common</em>.</p><p dir="ltr">The occurrence of injection site reactions usually decreases over time.</p><p dir="ltr">Tissue destruction (necrosis), abscess and mass at injection site are <em>uncommon </em>(may affect up to 1 in 100&nbsp;people).</p><p dir="ltr">See recommendations in section &ldquo;Warnings and precautions&rdquo; to minimise the risk of injection site reactions.</p><p dir="ltr">The injection site can become infected <em>(uncommon)</em>; the skin may become swollen tender and hard and the whole area could be very painful. If you experience any of these symptoms, contact your doctor for advice.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Certain <strong>laboratory tests</strong> may change. These changes are generally not noticed by the patient (no symptoms), are usually reversible and mild, and most often do not require particular treatment.</p><p dir="ltr">The number of red blood cells, white blood cells or platelets may decrease either individually <em>(very common)</em> or all at one time <em>(rare).</em> Possible symptoms resulting from these changes could include tiredness, reduced ability to fight infection, bruising or unexplained bleeding.</p><p dir="ltr">Liver function tests may be disturbed <em>(very common)</em>. Inflammation of the liver has also been reported <em>(uncommon)</em>. If you experience symptoms suggesting a liver disorder, such as loss of appetite accompanied by other symptoms such as nausea, vomiting, jaundice, please contact your doctor immediately (see above &ldquo;Tell your doctor immediately...&rdquo;).</p><p dir="ltr">&nbsp;</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Thyroid dysfunction</strong> is <em>uncommon</em>. The thyroid gland may function either excessively, or insufficiently. These changes in the thyroid activity are almost always not felt by the patient as symptoms; however, your doctor may recommend testing as appropriate.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>MS pseudo-relapse </strong>(<em>frequency not known</em>): There is a possibility that at the beginning of your treatment with Rebif you may experience symptoms that resemble those of a multiple sclerosis relapse. For example, your muscles may feel very tense or very weak, preventing you from moving as you want. In some cases, such symptoms are associated with fever or flu-like symptoms described above. If you notice any of these side effects talk to your doctor.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Other possible side effects include:</strong></p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr">Very common (may affect more than 1 in 10 people):</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p dir="ltr">&nbsp;</p><p dir="ltr">Common (may affect up to 1 in 10 people):</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Insomnia (sleeping difficulty)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea, nausea, vomiting</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itching, rash (skin eruptions)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle and joints pain</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fatigue, fever, chills</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hair loss</p><p dir="ltr">&nbsp;</p><p dir="ltr">Uncommon (may affect up to 1 in 100 people):</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hives</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Epileptic seizures</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Liver inflammation (hepatitis)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Breathing difficulties</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood clots such as deep venous thrombosis</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Disorders of the retina (back of the eye) such as inflammation or blood clots with consequent vision disorders (vision disturbances, loss of vision)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased sweating</p><p dir="ltr">&nbsp;</p><p dir="ltr">Rare (may affect up to 1 in 1,000 people):</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Suicide attempt</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serious skin reactions - some with mucosal lesions</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood clots in the small blood vessels that can affect your kidneys (thrombotic thrombocytopenic purpura or haemolytic uremic syndrome). Symptoms may include increased bruising, bleeding, fever, extreme weakness, headache, dizziness or light-headedness. Your doctor may find changes in your blood and the function of your kidneys.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Drug-induced lupus erythematosus: a side-effect of long-term use of Rebif. Symptoms may include muscle pain, joint pain and swelling, and rash. You may also experience other signs such as fever, weight loss, and fatigue. Usually symptoms disappear within one or two weeks after treatment is stopped.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kidney problems including scarring that may reduce your kidney function.</p><p dir="ltr">If you get some or all of these symptoms:</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; foamy urine</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fatigue</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling, particularly in the ankles and eyelids, and weight gain.</p><p dir="ltr">Tell your doctor as they may be signs of a possible kidney problem.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The following side effects were reported for interferon&nbsp;beta (frequency not known)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nervousness</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss of appetite</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dilatation of the blood vessels and palpitation</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Irregularities and/or changes in menstrual flow.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pulmonary arterial hypertension - a disease of severe narrowing of the blood vessels in the lungs resulting in high blood pressure in the blood vessels that carry blood from the heart to the lungs. Pulmonary arterial hypertension has been seen at various time points during treatment, including several years after starting treatment with Rebif.</p><p dir="ltr">&nbsp;</p><p dir="ltr">You should not stop or alter the medication without your doctor&rsquo;s advice.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Children and teenagers</strong></p><p dir="ltr">Side effects in children and teenagers are similar to those observed in adults.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Keep this medicine out of the sight and reach of children.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Do not use this medicine after the expiry date which is stated on the label after EXP.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Store in a refrigerator (2&deg;C&nbsp;&ndash;&nbsp;8&deg;C).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Do not freeze. <u>(To prevent accidental freezing, avoid placing near the freezer compartment).</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">For the purpose of ambulatory use, you may remove Rebif from the refrigerator and store it not above 25&deg;C for one single period of up to 14&nbsp;days. Rebif must then be returned to the refrigerator and used before the expiry date.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Store in the original package in order to protect from light.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Do not use this medicine if you notice any visible signs of deterioration such as if the solution is no longer clear or if it contains particles.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away of medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">What Rebif contains<br />&bull; The active substance is interferon beta-1a. Each syringe contains 44 micrograms, corresponding to 12 million International Units (IU) of interferon beta-1a. Page 7 of 8<br />32<br />&bull;The other ingredients are mannitol, poloxamer 188, L-methionine, benzyl alcohol, sodiumacetate, acetic acid, sodium hydroxide and water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Rebif is available as a solution for injection in a pre-filled syringe with a fixed needle for self-administration. Rebif solution is clear to opalescent. The pre-filled syringe is ready for use and contains 0.5 mL of solution. Rebif is available in packs of 1, 3, 12 and 36 pre-filled syringes. Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Marketing Authorisation Holder</strong></p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr">Merck Serono SA</p><p dir="ltr">Zone industrielle de l&#39;Ouriettaz</p><p dir="ltr">1170 Aubonne</p><p dir="ltr">&nbsp;Switzerland</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Manufacturer</strong></p><p dir="ltr">Merck Serono S.p.A.</p><p dir="ltr">Via delle Magnolie 15</p><p dir="ltr">I-70026 Modugno (Bari)</p><p dir="ltr">Italy</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 03 March 2020 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي عقار ريبيف إلى فئة من الأدوية تُعرف بالإنترفيرونات. وهي عبارة عن مواد طبيعية تنقل الرسائل بين الخلايا. ينتج الجسم الإنترفيرونات وتؤدي دورًا جوهريًا في جهاز المناعة. ومن خلال آليات ليست مفهومة بشكل كامل، تساعد الإنترفيرونات على الحد من تضرر الجهاز العصبي المركزي المصاحب للتصلب المتعدد.</p><p>&nbsp;</p><p dir="RTL">ريبيف عبارة عن بروتين قابل للذوبان عالي النقاء يشبه الإنترفيرون بيتا الطبيعي الذي يتم إنتاجه في الجسم البشري.</p><p>&nbsp;</p><p dir="RTL">يُستخدم ريبيف لعلاج التصلب المتعدد. وقد أثبت قدرته على خفض عدد وشدة الانتكاسات وإبطاء تدهور الإعاقة. مصرح باستخدامه أيضًا للمرضى الذين عانوا من حدث سريري واحد من المرجح أنه علامة أولى على التصلب المتعدد.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تستعمل ريبيف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك حساسية تجاه الإنترفيرون بيتا الطبيعي أو المأشوب أو أي من المكونات الأخرى لهذا الدواء (المذكورة في القسم 6).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من اكتئاب شديد في الوقت الراهن.</p><p>&nbsp;</p><p>التحذيرات والاحتياطات</p><p dir="RTL">استشر الطبيب أو الصيدلي أو الممرضة قبل استعمال ريبيف.</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي عدم استعمال ريبيف إلا تحت إشراف طبيبك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قبل العلاج بعقار ريبيف، اقرأ النصائح المقدمة تحت &quot;كيفية استعمال ريبيف&quot; واتبعها بعناية لتقلل من خطر تنخر موضع الحقن (تهتك الجلد وتلف الأنسجة) الذي أبلغ عنه مرضى عُولجوا بعقار ريبيف. إذا عانيت من تفاعلات موضعية متعبة، فاتصل بطبيبك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحدث مع طبيبك أو الصيدلي قبل أخذ ريبيف، إذا كنت تعاني من حساسية (فرط تحسس) تجاه أي أدوية أخرى.</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تحدث جلطات دموية في الأوعية الدموية الصغيرة خلال علاجك. قد تؤثر هذه الجلطات الدموية على كليتيك. قد يحدث هذا بعد بدء استعمال ريبيف بعدة أسابيع إلى <u>عدة سنواتٍ</u>. قد يود طبيبك فحص ضغط دمك، ودمك (عدد الصفيحات)، ووظائف كليتك.</p><p>&nbsp;</p><p dir="RTL">أبلغ طبيبك إذا كنت تعاني من مرض في</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نخاع العظم،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكلية،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكبد،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القلب،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدرقية،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أو إذا عانيت من الاكتئاب،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أو إذا كان لديك أي تاريخ لنوبات صرعية،</p><p dir="RTL">حتى يتمكن من مراقبة علاجك عن كثب ومراقبة أي تفاقم لهذه الحالات.</p><p>&nbsp;</p><p>ريبيف والأدوية الأخرى</p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تستعمل أيّ أدوية أخرى أو استعملتها مؤخراً أو قد تستعملها. ينبغي تحديدًا أن تبلغ طبيبك إذا كنت تستخدم أدوية مضادة للصرع أو الاكتئاب.</p><p>&nbsp;</p><p>الحمل والرضاعة</p><p dir="RTL">إذا كنتِ حاملاً، أو تعتقدين أنكِ حامل أو تخططين لإنجاب طفل، فاطلبي نصيحة طبيبكِ أو الصيدلي قبل أخذ هذا الدواء.</p><p dir="RTL">لا توجد آثار ضارة متوقعة على الطفل/الرضيع الذي يتلقى رضاعة طبيعية. يمكن استعمال ريبيف خلال الرضاعة الطبيعية.</p><p>&nbsp;</p><p>القيادة واستعمال الآلات</p><p dir="RTL">قد تؤثر آثار المرض نفسه أو علاجه على قدرتك على القيادة أو استعمال الآلات. ينبغي أن تناقش هذا مع طبيبك إذا كنت قلقًا.</p><p>&nbsp;</p><p>يحتوي ريبيف على كحول بنزيلي</p><p dir="RTL">يحتوي ريبيف على 2.5 ملغ كحول بنزيلي في الجرعة. ممنوع إعطاؤه للأطفال المبتسرين أو المواليد الجدد. قد يسبب تفاعلات سامة وتفاعلات تحسسية للرضع والأطفال حتى عمر 3 سنواتٍ.</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتعين عليك استعمال هذا الدواء دومًا بحسب توجيهات الطبيب تمامًا. ارجع لطبيبك إذا لم تكن متأكّدًا.</p><p>&nbsp;</p><p>الجرعة</p><p dir="RTL"><em>المرضى الذين عانوا من حدث سريري واحد</em></p><p dir="RTL">الجرعة المعتادة هي 44 ميكروغرامًا (12 مليون وحدة دولية) يتم إعطاؤها ثلاث مراتٍ أسبوعيًا.</p><p>&nbsp;</p><p dir="RTL"><em>مرضى التصلب المتعدد</em></p><p dir="RTL">الجرعة المعتادة هي 44 ميكروغرامًا (12 مليون وحدة دولية) يتم إعطاؤها ثلاث مراتٍ أسبوعيًا.</p><p>&nbsp;</p><p dir="RTL">يُوصى بجرعة مخفضة 22 ميكروغرامًا (6 مليون وحدة دولية) ثلاث مراتٍ أسبوعيًا للمرضى الذين لا يمكنهم تحمل الجرعة الأعلى.</p><p>&nbsp;</p><p dir="RTL">ينبغي أخذ ريبيف ثلاث مراتٍ أسبوعيًا، وإذا أمكن:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في نفس الأيام الثلاث كل أسبوع (بفاصل 48 ساعة على الأقل؛ مثل الإثنين والأربعاء والجمعة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في نفس الوقت من اليوم (يفضل في المساء).</p><p>&nbsp;</p><p>الاستعمال للأطفال والمراهقين (من عمر عامين إلى 17 عامًا)</p><p dir="RTL">لم يتم عمل دراسات سريرية رسمية على أطفال أو مراهقين. ومع هذا تتوفر بعض البيانات السريرية التي تشير إلى أن بيانات السلامة الخاصة بالأطفال والمراهقين الذين يتلقون ريبيف 22 ميكروغرامًا أو ريبيف 44 ميكروغرامًا ثلاث مراتٍ أسبوعيًا مشابهة لتلك التي تُلاحظ لدى البالغين.</p><p>&nbsp;</p><p>الاستعمال للأطفال (تحت عمر عامين)</p><p dir="RTL">لا يوصى باستعمال ريبيف للأطفال تحت عمر عامين.</p><p>&nbsp;</p><p>طريقة الحقن</p><p dir="RTL">ريبيف مخصص للحقن تحت الجلد.</p><p dir="RTL">يجب أن يتم أخذ الحقنة (الحقن) الأولى تحت إشراف متخصص رعاية صحية مؤهل مناسب. بعد تلقي التدريب الكافي، يمكنك أنت، أو قريب، أو صديق، أو اختصاصي رعاية، استعمال محاقن ريبيف لأخذ الدواء في المنزل. يمكن أيضًا أخذه بحاقن أوتوماتيكي مناسب.</p><p>&nbsp;</p><p>لاستعمال ريبيف، يُرجى قراءة التعليمات التالية بعناية:</p><p dir="RTL">هذا الدواء للاستخدام مرة واحدة. ينبغي عدم استعمال غير المحلول الشفاف إلى الغائم الخالي من الجزيئات وعلامات التلف المرئية.</p><p>&nbsp;</p><p dir="RTL"><em>طريقة حقن ريبيف</em></p><table dir="rtl" border="0" cellspacing="0" cellpadding="0" style="width:631px"><tbody><tr><td style="vertical-align:top"><p dir="LTR"><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
   coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
   filled="f" stroked="f">
   <v:stroke joinstyle="miter"/>
   <v:formulas>
    <v:f eqn="if lineDrawn pixelLineWidth 0"/>
    <v:f eqn="sum @0 1 0"/>
    <v:f eqn="sum 0 0 @1"/>
    <v:f eqn="prod @2 1 2"/>
    <v:f eqn="prod @3 21600 pixelWidth"/>
    <v:f eqn="prod @3 21600 pixelHeight"/>
    <v:f eqn="sum @0 0 1"/>
    <v:f eqn="prod @6 1 2"/>
    <v:f eqn="prod @7 21600 pixelWidth"/>
    <v:f eqn="sum @8 21600 0"/>
    <v:f eqn="prod @7 21600 pixelHeight"/>
    <v:f eqn="sum @10 21600 0"/>
   </v:formulas>
   <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
   <o:lock v:ext="edit" aspectratio="t"/>
  </v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1027" type="#_x0000_t75"
   alt="injection" style='width:60pt;height:117.75pt;visibility:visible;
   mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/M272521/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title="injection"/>
  </v:shape><![endif]--><img width="80" height="157" alt="injection" src="file:///C:/Users/M272521/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></p></td><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اختر موضع حقن. سوف ينصحك طبيبك بخصوص مواضع الحقن الممكنة (تشمل المواضع الجيدة أعلى الفخذين وأسفل البطن). أمسك بالمحقنة وكأنها قلم أو سهم. ويوصى بأن تتعقب مواضع الحقن وتعيد تدويرها، حتى لا يتم حقن منطقة واحدة بتكرارية عالية لتقلل من خطر تنخر موضع الحقن.</p><p dir="RTL">ملحوظة: لا تستخدم أي مناطق تشعر فيها بكتل أو عقد صلبة أو ألم؛ وتحدث مع طبيبك أو مختص الرعاية الصحية بخصوص أي شيء تجده.</p></td></tr></tbody></table><p><em>&nbsp;</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اغسل يديك جيدًا بالماء والصابون.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخرِج محقنة ريبيف من العلبة المغلفة بأن تقشر الغطاء البلاستيك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قبل الحقن، استخدم مسحة كحول لتنظيف الجلد في موضع الحقن. اترك الجلد يجف. إذا بقي أثر من الكحول على الجلد، فقد تشعر بإحساس لاسع.</p><p>&nbsp;</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="LTR"><!--[if gte vml 1]><v:shape
   id="Рисунок_x0020_1" o:spid="_x0000_i1026" type="#_x0000_t75" style='width:92.25pt;
   height:84.75pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/M272521/AppData/Local/Temp/msohtmlclip1/01/clip_image003.png"
    o:title="" cropleft="2797f" cropright="3595f"/>
  </v:shape><![endif]--><img width="123" height="113" src="file:///C:/Users/M272521/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif" /></p></td><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمسك الجلد بلطف حول الموضع (كي ترفعه قليلاً).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلال إراحة رسغك على الجلد قرب الموضع، أدخل الإبرة بزاوية قائمة في الجلد مباشرةً بحركة سريعة ثابتة.</p></td></tr><tr><td style="vertical-align:top"><p dir="LTR">&nbsp;</p></td><td style="vertical-align:top"><p dir="LTR">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="LTR"><!--[if gte vml 1]><v:shape
   id="Рисунок_x0020_2" o:spid="_x0000_i1025" type="#_x0000_t75" style='width:92.25pt;
   height:93.75pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/M272521/AppData/Local/Temp/msohtmlclip1/01/clip_image005.png"
    o:title="" croptop="6658f" cropbottom="14f" cropleft="4291f" cropright="3511f"/>
  </v:shape><![endif]--><img width="123" height="125" src="file:///C:/Users/M272521/AppData/Local/Temp/msohtmlclip1/01/clip_image006.gif" /></p></td><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احقن الدواء مستعينًا بدفع بطيء ثابت (ادفع الكبّاس كاملاً إلى أن تفرغ المحقنة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمسك بماسحة على موضع الحقن. انزع الإبرة من الجلد.</p></td></tr></tbody></table><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دلِّك برفق موضع الحقن بكرة قطن جافة أو شاش.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تخلص من كل المواد المستخدمة: بمجرد انتهائك من حقنك، تخلص فورًا من المحقنة في وحدة نفايات مناسبة.</p><p>&nbsp;</p><p>إذا استعملت كمية من ريبيف أكبر مما يجب</p><p dir="RTL">في حالة الجرعة الزائدة، اتصل بطبيبك فورًا.</p><p>&nbsp;</p><p>إذا نسيت استعمال ريبيف</p><p dir="RTL">إذا فوتّ جرعة، فواصل الحقن من يوم الجرعة التالية المقررة. لا تستعمل جرعة مزدوجة للتعويض عن جرعة قد نسيتها.</p><p>&nbsp;</p><p>إذا أوقفت استعمال ريبيف</p><p dir="RTL">قد لا يتم ملاحظة تأثيرات ريبيف فوريًا. لهذا، ينبغي ألّا توقف استعمال ريبيف وإنما واصل استعماله بانتظام لتحقيق النتيجة المرجوة. إذا لم تكن متأكدًا من المنافع، فيُرجى استشارة طبيبك.</p><p>&nbsp;</p><p dir="RTL">ينبغي ألّا توقف العلاج دون استشارة طبيبك أولاً.</p><p>&nbsp;</p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي أو الممرضة إذا كانت لديك أي أسئلة أخرى حول استعمال هذا الدواء.</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p><strong>&nbsp;</strong></p><p dir="RTL">قد يسبب هذا الدواء، شأنه شأن جميع الأدوية، آثاراً جانبية، على الرغم من أنها لا تصيب الجميع.</p><p>&nbsp;</p><p>أبلغ طبيبك فورًا وأوقف استعمال ريبيف إذا أصابتك أي من الآثار الجانبية الخطيرة التالية:</p><p><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تفاعلات تحسسية (فرط تحسس) خطيرة</strong>. إذا شعرت بعد حقن ريبيف مباشرةً بصعوبة تنفس مفاجئة، قد تظهر مصاحبةً لتورم في الوجه أو الشفتين أو اللسان أو الحلق، وحمى قراصية، وحكّة في كامل الجسم، وإحساس بالضعف أو الإغماء، اتصل بطبيبك فورًا أو اطلب الرعاية الطبية العاجلة. هذه التفاعلات <em>نادرة </em>(قد تصيب حتى واحد من كل 1000 شخص).</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أبلغ طبيبك فورًا إذا أصابتك أي من الأعراض المحتملة التالية <strong>لمشكلة في الكبد</strong>: يرقان (اصفرار الجلد أو الأجزاء البيضاء من العين)، وحكّة واسعة الانتشار، وفقدان شهية مصحوب بغثيان وقيء، وسهولة تكدم الجلد. قد تصحب مشاكل الكبد الشديدة علامات إضافية؛ مثل صعوبة التركيز، والنعاس، والارتباك.</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الاكتئاب </strong><em>شائع </em>(قد يصيب حتى واحد من كل 10 أشخاص) لدى مرضى التصلب المتعدد الذين يعالَجون. إذا شعرت أنك <strong>مكتئب أو تأتيك أفكار انتحارية</strong>، فأبلغ طبيبك فورًا.</p><p>&nbsp;</p><p>استشر طبيبك إذا تعرضت لأي من الآثار الجانبية التالية:</p><p><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الأعراض الشبيهة بالأنفلونزا، </strong>مثل الصداع، والحمى، وقشعريرة، وآلام العضلات والمفاصل؛ والتعب، والغثيان <em>شائعة جدًا </em>(قد تصيب أكثر من واحد من كل 10 أشخاص).</p><p dir="RTL">عادةً ما تكون هذه الأعراض خفيفة، وهي أكثر شيوعًا عند بدء العلاج وتقل بالاستعمال المستمر.</p><p dir="RTL">للعمل على تقليل هذه الأعراض، قد ينصحك طبيبك بأخذ مسكّن ألم خافض للحمى قبل جرعة ريبيف ثم لمدة 24 ساعة بعد كل حقن.</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ردود الفعل في موضع الحقن </strong>بما في ذلك الاحمرار والتورم وتغير اللون والالتهاب والألم وتهتك الجلد <em>شائعة جدًا</em>.</p><p dir="RTL">عادةً ما يخف حدوث التفاعلات في موضع الحقن بمرور الوقت.</p><p dir="RTL">تلف الأنسجة (التنخر) وظهور خُرَّاج وكتلة في موضع الحقن أعراض <em>غير شائعة </em>(قد تصيب حتى واحد من كل 100 شخص).</p><p dir="RTL">انظر التوصيات في قسم &quot;التحذيرات والاحتياطات&quot; لتقليل خطر التفاعلات في موضع الحقن.</p><p>&nbsp;</p><p dir="RTL">قد تحدث عدوى في موضع الحقن (<em>غير شائعة</em>)؛ قد يصبح الجلد متورمًا وموجعًا عند اللمس وصلبًا وقد تصبح كامل المنطقة مؤلمة جدًا. إذا أصابتك أيٍ من هذه الأعراض، فاتصل بطبيبك طلبًا للنصيحة.</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تحدث تغيرات في <strong>فحوص مختبرية </strong>معينة. تكون هذه التغيرات غير ملحوظة عمومًا بالنسبة للمريض (لا أعراض)، وعادةً ما تكون عكوسة وخفيفة، ولا تتطلب علاجًا محددًا في معظم الأحيان.</p><p dir="RTL">قد ينخفض عدد خلايا الدم الحمراء أو خلايا الدم البيضاء أو الصفيحات إما بشكل منفرد <em>(شائع جدًا) </em>أو كلها في وقت واحد <em>(نادر). </em>يمكن أن تشمل الأعراض المحتملة الناتجة عن هذه التغيرات التعب، أو ضعف القدرة على مكافحة العدوى، أو التكدّم، أو النزيف غير المبرر.</p><p dir="RTL">قد تختل اختبارات وظائف الكبد <em>(شائع جدًا)</em>. تم أيضًا الإبلاغ عن التهاب الكبد <em>(غير شائع)</em>. إذا عانيت من أعراض تشير إلى اضطراب في الكبد، مثل فقدان الشهية المصحوب بأعراض أخرى كالغثيان أو القيء أو اليرقان، فيُرجى الاتصال بطبيبك فورًا (انظر أعلاه &quot;أبلغ طبيبك فورًا...&quot;).</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الخلل الوظيفي في الغدة الدرقية </strong><em>غير شائع</em>. قد تعمل الغدة الدرقية إما بإفراط أو بقصور. لا يشعر المريض دائمًا تقريبًا بهذه التغيرات في نشاط الدرقية كأعراض؛ ومع هذا قد يوصي طبيبك باختبار حسب الاقتضاء.</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الانتكاسة الزائفة للتصلب المتعدد </strong>(<em>معدل التكرار غير معروف</em>): في بداية علاجك بعقار ريبيف، توجد احتمالية أن تعاني من أعراض تشبه تلك الخاصة بانتكاسة التصلب المتعدد. على سبيل المثال، قد تشعر أن عضلاتك متوترة جدًا أو ضعيفة جدًا، لدرجة تمنعك من التحرك كما تشاء. تكون هذه الأعراض مصحوبة في بعض الحالات بالحمى أو الأعراض الشبيهة بالأنفلونزا المذكورة أعلاه. إذا لاحظت أيٍ من هذه الآثار الجانبية، فتحدث مع طبيبك.</p><p>&nbsp;</p><p>تشمل الآثار الجانبية المحتملة الأخرى:</p><p><strong>&nbsp;</strong></p><p dir="RTL">شائعة جدًا (قد تصيب أكثر من واحد من كل 10 أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p>&nbsp;</p><p dir="RTL">شائعة (قد تصيب حتى واحد من كل 10 أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأرق (صعوبة النوم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال، الغثيان، القيء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحكّة، الطفح (طفوح الجلد)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم العضلات والمفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعب، الحمى، القشعريرة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر</p><p>&nbsp;</p><p dir="RTL">غير شائعة (قد تصيب حتى واحد من كل 100 شخص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القشعريره</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النوبات الصرعية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبات التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التجلطات الدموية مثل الخثار الوريدي العميق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الشبكية (مؤخرة العين) مثل التهاب أو جلطات دموية ينشأ عنها اضطرابات في الإبصار (اضطرابات الإبصار، فقدان البصر)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة التعرّق</p><p>&nbsp;</p><p dir="RTL">نادرة (قد تصيب حتى واحد&nbsp;من كل 1000&nbsp;شخص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; محاولة الانتحار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التفاعلات الجلدية الخطيرة - بعضها مع آفات مخاطية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجلطات الدموية في الأوعية الدموية الصغيرة التي يمكنها التأثير على كليتيك (الفُرفُرِية القليلة الصفيحات الخثارية أو المتلازمة اليوريمية الانحلالية). قد تشمل الأعراض زيادة التكدّم، أو النزيف، أو الحمى، أو الضعف الشديد، أو الصداع، أو الدوّار، أو الدوخة. قد يجد طبيبك تغيرات في دمك وفي وظائف كليتيك.</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الذئبة الحمامية الناجمة عن الأدوية: أثر جانبي نتيجة استخدام ريبيف على المدى الطويل. قد تشمل الأعراض ألم العضلات، وألم المفاصل، والتورم، والطفح. قد تعاني أيضًا من علامات أخرى مثل الحمى، وخسارة الوزن، والتعب. عادةً ما تختفي الأعراض خلال أسبوع أو أسبوعين بعد وقف العلاج.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل الكلى بما في ذلك التندب الذي قد يقلل وظائف كليتك. إذا أُصِبت ببعض أو كل هذه الأعراض:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البول الرغوي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التورم، تحديدًا في الكاحلين والجفون، وزيادة الوزن. أبلغ طبيبك لأنها قد تكون علامات لمشكلة محتملة في الكلية.</p><p>&nbsp;</p><p dir="RTL">تم الإبلاغ عن الآثار الجانبية التالية مع إنترفيرون بيتا (معدل التكرار غير معروف)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدُوار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العصبية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توسع الأوعية الدموية والخفقان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم انتظام و/أو تغيرات في تدفق الدورة الشهرية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم الشرياني الرئوي - مرض تضيُّق شديد للأوعية الدموية في الرئتين ينتج عنه ضغط دم مرتفع في الأوعية الدموية التي تحمل الدم من القلب إلى الرئتين. لُوحظ ارتفاع ضغط الدم الشرياني الرئوي في نقاط زمنية مختلفة خلال العلاج، بما في ذلك بعد عدة سنوات من بدء العلاج بعقار ريبيف.</p><p>&nbsp;</p><p dir="RTL">يجب ألّا توقف العلاج أو تعدّله بدون استشارة طبيبك.</p><p>&nbsp;</p><p>الأطفال والمراهقين</p><p dir="RTL">الآثار الجانبية لدى الأطفال والمراهقين مشابهة لتلك التي لُوحظت لدى البالغين.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>&nbsp;</strong></p><p dir="RTL">احفظ هذا الدواء بعيدًا عن متناول الأطفال ورؤيتهم.</p><p>&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء صلاحيته المدوّن على الملصق بجوار الاختصار EXP (انتهاء الصلاحية).</p><p dir="RTL">يُحفظ في الثلاجة (ما بين 2 إلى 8 درجاتٍ مئوية).</p><p dir="RTL">ويُحظر تجميده. <u>(لمنع التجمد غير المقصود، تجنب وضعه بالقرب من حجيرة المجمّد).</u></p><p>&nbsp;</p><p dir="RTL">لغرض الاستخدام المتنقل، يمكنك إخراج ريبيف من المبّرد وحفظه في درجة حرارة لا تزيد عن 25 درجة مئوية لفترة زمنية واحدة أقصاها 14 يومًا. يجب بعدها إعادة ريبيف إلى المبرد واستخدامه قبل تاريخ انتهاء الصلاحية.</p><p>&nbsp;</p><p dir="RTL">احفظ الدواء في العبوة الأصلية لحمايته من الضوء.</p><p>&nbsp;</p><p dir="RTL">لا تستعمل هذا الدواء إذا لاحظت أيّ مؤشرات تدلّ على تلفه، كأن لا يعود المحلول شفافًا أو إذا احتوى على جزيئات.</p><p>&nbsp;</p><p dir="RTL">لا ترمِ أيّ أدوية في مياه الصرف أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. تساعد هذه التدابير على حماية البيئة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما يحتوي عليه ريبيف</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعّالة هي إنترفيرون بيتا-1أ. تحتوي كل محقنة على 44 ميكروغرامًا يعادل 12 مليون وحدة دولية (IU) إنترفيرون بيتا-1أ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي مانيتول، بولوكسامير 188، ل-مثيونين، كحول بنزيلي، أسيتات صوديوم، حمض أسيتيك، هيدروكسيد صوديوم، وماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>شكل ريبيف ومحتويات العبوة</p><p dir="RTL">يتوفر ريبيف كمحلول للحقن في محقنة معبأة مسبقًا مع إبرة مثبتة للاستخدام الذاتي. محلول ريبيف شفاف إلى غائم. المحقنة المعبأة مسبقًا جاهزة للاستخدام وتحتوي على 0.5 مل من المحلول.</p><p dir="RTL">يتوفر ريبيف في عبوات 1 و3 و12 و36 محقنة معبأة مسبقًا. قد لا تُسوَّق جميع أحجام العلب.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ميرك سيرونو SA</p><p dir="RTL">المنطقة الصناعية أووريتاز</p><p dir="RTL">1170 اوبون</p><p dir="RTL">سويسرا</p><p>&nbsp;</p><p>جهة التصنيع</p><p dir="RTL">ميرك سيرنو اس بي اي</p><p dir="RTL">شارع ماغنوليا 15</p><p dir="RTL">I-70026 Modugno (باري)</p><p dir="RTL">إيطاليا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            جرت آخر مراجعة لهذه النشرة في 03 مارس 2020 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Rebif 44 micrograms solution for injection in pre-filled syringe
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Each pre filled syringe (0.5 mL) contains 44 micrograms (12 MIU*) of interferon beta 1a**.

* Million International Units measured by cytopathic effect (CPE) bioassay against the in house interferon beta 1a standard which is calibrated against the current international NIH standard (GB 23 902 531).
** produced in Chinese hamster ovary Cells (CHO K1) by recombinant DNA technology.

Excipient with known effect: 2.5 mg benzyl alcohol
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection in pre-filled syringe.
Clear to opalescent solution, with pH 3.5 to 4.5 and osmolarity 250 to 450 mOsm/L.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Rebif is indicated for the treatment of</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; patients with a single demyelinating event with an active inflammatory process, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis (see section 5.1)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; patients with relapsing multiple sclerosis. In clinical trials, this was characterised by two or more acute exacerbations in the previous two years (see section&nbsp;5.1).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Efficacy has not been demonstrated in patients with secondary progressive multiple sclerosis without ongoing relapse activity (see section&nbsp;5.1).</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Treatment should be initiated under supervision of a physician experienced in the treatment of the disease.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Rebif is available in three&nbsp;strengths: 8.8&nbsp;micrograms, 22&nbsp;micrograms and 44&nbsp;micrograms. For patients initiating treatment with Rebif, Rebif 8.8&nbsp;micrograms and Rebif 22&nbsp;micrograms are available in a pack that corresponds to the patient needs for the first month of therapy.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Posology</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">When first starting treatment with Rebif, in order to allow tachyphylaxis to develop thus reducing adverse reactions it is recommended that patients be started at 8.8&nbsp;micrograms dose subcutaneously and the dose be increased over a 4&nbsp;week period to the targeted dose, according to the following schedule:</p><p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:74%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Recommended<br />Titration</p><p>(% of final dose)</p></td><td style="vertical-align:top"><p>Titration dose for Rebif 44&nbsp;micrograms three&nbsp;times&nbsp;per&nbsp;week&nbsp;(tiw)</p></td></tr><tr><td style="vertical-align:top"><p>Weeks 1-2</p></td><td style="vertical-align:top"><p>20%</p></td><td style="vertical-align:top"><p>8.8&nbsp;micrograms tiw</p></td></tr><tr><td style="vertical-align:top"><p>Weeks 3&ndash;4</p></td><td style="vertical-align:top"><p>50%</p></td><td style="vertical-align:top"><p>22&nbsp;micrograms tiw</p></td></tr><tr><td style="vertical-align:top"><p>Weeks 5+</p></td><td style="vertical-align:top"><p>100%</p></td><td style="vertical-align:top"><p>44&nbsp;micrograms tiw</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>First demyelinating event</u></em></p><p dir="ltr">The posology for patients who have experienced a first demyelinating event is 44&nbsp;micrograms of Rebif given three times per week by subcutaneous injection.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Relapsing multiple sclerosis</u></em></p><p dir="ltr">The recommended posology of Rebif is 44&nbsp;micrograms given three&nbsp;times per&nbsp;week by subcutaneous injection. A lower dose of 22&nbsp;micrograms, also given three&nbsp;times per&nbsp;week by subcutaneous injection, is recommended for patients who cannot tolerate the higher dose in view of the treating specialist.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Paediatric population</u></em></p><p dir="ltr">No formal clinical trials or pharmacokinetic studies have been conducted in children or adolescents. However, a paediatric retrospective cohort study collected safety data with Rebif from medical records in children (n=52) and adolescents (n=255). The results of this study suggest that the safety profile in children (2 to 11&nbsp;years old) and in adolescents (12 to 17&nbsp;years old) receiving Rebif 22&nbsp;micrograms or 44&nbsp;micrograms subcutaneous three times per week is similar to that seen in adults.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The safety and efficacy of Rebif in children below 2&nbsp;years of age have not yet been established. Rebif should not be used in this age group.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Method of administration</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Rebif is administered by subcutaneous injection. Prior to injection and for an additional 24&nbsp;hours after each injection, an antipyretic analgesic is advised to decrease flu‑like symptoms associated with Rebif administration.</p><p dir="ltr">&nbsp;</p><p dir="ltr">At the present time, it is not known for how long patients should be treated. Safety and efficacy with Rebif have not been demonstrated beyond 4&nbsp;years of treatment. It is recommended that patients should be evaluated at least every second year in the 4‑year period after initiation of treatment with Rebif and a decision for longer term treatment should then be made on an individual basis by the treating physician.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to natural or recombinant interferon beta or to any of the excipients listed in section 6.1.
•	Current severe depression and/or suicidal ideation (see sections 4.4 and 4.8).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Traceability</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p dir="ltr"><em>&nbsp;</em></p><p dir="ltr"><u>General recommendations</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Patients should be informed of the most frequent adverse reactions associated with interferon&nbsp;beta administration, including symptoms of the flu‑like syndrome (see section&nbsp;4.8). These symptoms tend to be most prominent at the initiation of therapy and decrease in frequency and severity with continued treatment.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Thrombotic microangiopathy (TMA)</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Cases of thrombotic microangiopathy, manifested as thrombotic thrombocytopenic purpura (TTP) or haemolytic uraemic syndrome (HUS), including fatal cases, have been reported with interferon beta products. Events were reported at various time points during treatment and may occur several weeks to several years after starting treatment with interferon beta. Early clinical features include thrombocytopenia, new onset hypertension, fever, central nervous system symptoms (e.g. confusion, paresis) and impaired renal function. Laboratory findings suggestive of TMA include decreased platelet counts, increased serum lactate dehydrogenase (LDH) due to haemolysis and schistocytes (erythrocyte fragmentation) on a blood film. Therefore if clinical features of TMA are observed, further testing of blood platelet levels, serum LDH, blood films and renal function is recommended. If TMA is diagnosed, prompt treatment is required (considering plasma exchange) and immediate discontinuation of Rebif is recommended.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Depression and suicidal ideation</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Rebif should be administered with caution to patients with previous or current depressive disorders in particular to those with antecedents of suicidal ideation (see section&nbsp;4.3). Depression and suicidal ideation are known to occur in increased frequency in the multiple sclerosis population and in association with interferon use. Patients treated with Rebif should be advised to immediately report any symptoms of depression and/or suicidal ideation to their prescribing physician. Patients exhibiting depression should be monitored closely during therapy with Rebif and treated appropriately. Cessation of therapy with Rebif should be considered (see sections&nbsp;4.3 and&nbsp;4.8).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Seizure disorders</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Rebif should be administered with caution to patients with a history of seizures, to those receiving treatment with anti-epileptics, particularly if their epilepsy is not adequately controlled with antiepileptics (see sections&nbsp;4.5 and&nbsp;4.8).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Cardiac disease</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Patients with cardiac disease, such as angina, congestive heart failure or arrhythmia, should be closely monitored for worsening of their clinical condition during initiation of therapy with interferon&nbsp;beta‑1a. Symptoms of the flu‑like syndrome associated with interferon&nbsp;beta‑1a therapy may prove stressful to patients with cardiac conditions.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Injection site necrosis</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">Injection site necrosis (ISN) has been reported in patients using Rebif (see section&nbsp;4.8). To minimise the risk of injection site necrosis patients should be advised to:</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; use an aseptic injection technique,</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rotate the injection sites with each dose.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The procedure for the self-administration by the patient should be reviewed periodically especially if injection site reactions have occurred.</p><p dir="ltr">&nbsp;</p><p dir="ltr">If the patient experiences any break in the skin, which may be associated with swelling or drainage of fluid from the injection site, the patient should be advised to consult with their physician before continuing injections with Rebif. If the patient has multiple lesions, Rebif should be discontinued until healing has occurred. Patients with single lesions may continue provided that the necrosis is not too extensive.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Hepatic dysfunction</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">In clinical trials with Rebif, asymptomatic elevations of hepatic transaminases (particularly alanine aminotransferase (ALT)) were common and 1‑3% of patients developed elevations of hepatic transaminases above 5&nbsp;times the upper limit of normal (ULN). In the absence of clinical symptoms, serum ALT levels should be monitored prior to the start of therapy, at months&nbsp;1, 3 and&nbsp;6 on therapy and periodically thereafter. Dose reduction of Rebif should be considered if ALT rises above 5&nbsp;times the ULN, and gradually re‑escalated when enzyme levels have normalized. Rebif should be initiated with caution in patients with a history of significant liver disease, clinical evidence of active liver disease, alcohol abuse or increased serum ALT (&gt;2.5&nbsp;times ULN). Treatment with Rebif should be stopped if icterus or other clinical symptoms of liver dysfunction appear.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Rebif, like other interferons&nbsp;beta, has a potential for causing severe liver injury including acute hepatic failure (see section&nbsp;4.8). The majority of the cases of severe liver injury occurred within the first six months of treatment. The mechanism for the rare symptomatic hepatic dysfunction is not known. No specific risk factors have been identified.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Renal and urinary disorders</u></p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Nephrotic syndrome</em></p><p dir="ltr">&nbsp;</p><p dir="ltr">Cases of nephrotic syndrome with different underlying nephropathies including collapsing focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD), membranoproliferative glomerulonephritis (MPGN) and membranous glomerulopathy (MGN) have been reported during treatment with interferon-beta products. Events were reported at various time points during treatment and may occur after several years of treatment with interferon-beta. Periodic monitoring of early signs or symptoms, e.g. oedema, proteinuria and impaired renal function is recommended, especially in patients at higher risk of renal disease. Prompt treatment of nephrotic syndrome is required and discontinuation of treatment with Rebif should be considered.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Laboratory abnormalities</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">Laboratory abnormalities are associated with the use of interferons. The overall incidence of these is slightly higher with Rebif&nbsp;44 than Rebif&nbsp;22&nbsp;micrograms. Therefore, in addition to those laboratory tests normally required for monitoring patients with multiple sclerosis, liver enzyme monitoring and complete and differential blood cell counts and platelet counts are recommended at regular intervals (1, 3&nbsp;and 6&nbsp;months) following introduction of Rebif therapy and then periodically thereafter in the absence of clinical symptoms. These should be more frequent when initiating Rebif&nbsp;44&nbsp;micrograms.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Thyroid disorders</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">Patients being treated with Rebif may occasionally develop new or worsening thyroid abnormalities. Thyroid function testing is recommended at baseline and if abnormal, every 6‑12&nbsp;months following initiation of therapy. If tests are normal at baseline, routine testing is not needed but should be performed if clinical findings of thyroid dysfunction appear (see section&nbsp;4.8).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Severe renal or hepatic failure and severe myelosuppression</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">Caution should be used, and close monitoring considered when administering interferon&nbsp;beta‑1a to patients with severe renal and hepatic failure and to patients with severe myelosuppression.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Neutralising antibodies</p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">Serum neutralising antibodies against interferon&nbsp;beta‑1a may develop. The precise incidence of antibodies is as yet uncertain. Clinical data suggest that after 24&nbsp;to 48&nbsp;months of treatment with Rebif&nbsp;44&nbsp;micrograms, approximately 13&nbsp;to 14%&nbsp;of&nbsp;patients develop persistent serum antibodies to interferon&nbsp;beta‑1a. The presence of antibodies has been shown to attenuate the pharmacodynamic response to interferon&nbsp;beta‑1a (beta‑2&nbsp;microglobulin and neopterin). Although the clinical significance of the induction of antibodies has not been fully elucidated, the development of neutralising antibodies is associated with reduced efficacy on clinical and MRI variables. If a patient responds poorly to therapy with Rebif, and has neutralising antibodies, the treating physician should reassess the benefit/risk ratio of continued Rebif therapy.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The use of various assays to detect serum antibodies and differing definitions of antibody positivity limits the ability to compare antigenicity among different products.</p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><u>Other forms of multiple sclerosis</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Only sparse safety and efficacy data are available from non-ambulatory patients with multiple sclerosis. Rebif has not yet been investigated in patients with primary progressive multiple sclerosis and should not be used in these patients.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Benzyl alcohol</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">This medicinal product contains 2.5&nbsp;mg benzyl alcohol per dose.</p><p dir="ltr">It must not be given to premature babies or neonates. It may cause toxic reactions and anaphylactoid reactions in infants and children up to 3&nbsp;years old.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">No interaction studies have been performed with interferon&nbsp;beta‑1a in humans.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Interferons have been reported to reduce the activity of hepatic cytochrome&nbsp;P450‑dependent enzymes in humans and animals. Caution should be exercised when administering Rebif in combination with medicinal products that have a narrow therapeutic index and are largely dependent on the hepatic cytochrome&nbsp;P450 system for clearance, e.g.&nbsp;antiepileptics and some classes of antidepressants.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The interaction of Rebif with corticosteroids or adrenocorticotropic hormone (ACTH) has not been studied systematically. Clinical studies indicate that multiple sclerosis patients can receive Rebif and corticosteroids or ACTH during relapses</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Pregnancy</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">A large amount of data (more than 1,000 pregnancy outcomes) from registries and post-marketing experience indicates no increased risk of major congenital anomalies after pre-conception exposure to interferon beta or such exposure during the first trimester of pregnancy. However, the duration of exposure during the first trimester is uncertain, because data were collected when interferon beta use was contraindicated during pregnancy, and treatment likely interrupted when the pregnancy was detected and/or confirmed. Experience with exposure during the second and third trimester is very limited.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Based on animal data (see section&nbsp;5.3), there is a possibly increased risk for spontaneous abortion. The risk of spontaneous abortions in pregnant women exposed to interferon beta cannot adequately be evaluated based on the currently available data, but the data do not suggest an increased risk so far.</p><p dir="ltr">&nbsp;</p><p dir="ltr">If clinically needed, the use of Rebif may be considered during pregnancy</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Breast-feeding</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Limited information available on the transfer of interferon beta-1a into breast milk, together with the chemical/physiological characteristics of interferon beta, suggests that levels of interferon beta-1a excreted in human milk are negligible. No harmful effects on the breastfed newborn/infant are anticipated.</p><p dir="ltr">Rebif can be used during breast-feeding.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Fertility</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">The effects of Rebif on fertility have not been investigated.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Central nervous system-related adverse events associated with the use of interferon&nbsp;beta (e.g.&nbsp;dizziness) might influence the patient&#39;s ability to drive or use machines (see section&nbsp;4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Summary of the safety profile</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">The highest incidence of adverse reactions associated with Rebif therapy is related to flu‑like syndrome. Flu‑like symptoms tend to be most prominent at the initiation of therapy and decrease in frequency with continued treatment. Approximately&nbsp;70% of patients treated with Rebif can expect to experience the typical interferon flu-like syndrome within the first six months after starting treatment. Approximately&nbsp;30% of patients will also experience reactions at the injection site, predominantly mild inflammation or erythema. Asymptomatic increases in laboratory parameters of hepatic function and decreases in white blood cells are also common.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The majority of adverse reactions observed with interferon&nbsp;beta‑1a are usually mild and reversible, and respond well to dose reductions. In case of severe or persistent undesirable effects, the dose of Rebif may be temporarily lowered or interrupted, at the discretion of the physician.</p><p dir="ltr">&nbsp;</p><p dir="ltr">List of adverse reactions</p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">The adverse reactions presented have been identified from clinical studies as well as from post-marketing reports <em>(an asterisk [*] indicates adverse reactions identified during post-marketing surveillance)</em>. The following definitions apply to the frequency terminology used hereafter: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000), frequency not known (cannot be estimated from the available data).</p><p dir="ltr"><em><u>&nbsp;</u></em></p><p dir="ltr"><em><u>Blood and the lymphatic system disorders</u></em></p><p dir="ltr">Very common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Neutropenia, lymphopenia, leukopenia, thrombocytopenia, anaemia</p><p dir="ltr">Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thrombotic microangiopathy including thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome* (class label for interferon beta products, see section 4.4), pancytopenia<em>*</em></p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Endocrine disorders</u></em></p><p dir="ltr">Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thyroid dysfunction, most often presenting as hypothyroidism or hyperthyroidism</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Immune system disorders</u></em></p><p dir="ltr">Rare: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anaphylactic reactions*</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Hepatobiliary disorders</u></em></p><p dir="ltr">Very common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Asymptomatic transaminase increase</p><p dir="ltr">Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe elevations in transaminases</p><p dir="ltr">Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hepatitis with or without icterus*</p><p dir="ltr">Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hepatic failure* (see section&nbsp;4.4), autoimmune hepatitis*</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Psychiatric disorders</u></em></p><p dir="ltr">Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depression, insomnia</p><p dir="ltr">Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Suicide attempt*</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Nervous system disorders</u></em></p><p dir="ltr">Very common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p dir="ltr">Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Seizures*</p><p dir="ltr">Frequency not known:&nbsp;&nbsp;&nbsp; Transient neurological symptoms (i.e. hypoesthesia, muscle spasm, paraesthesia, difficulty in walking, musculoskeletal stiffness) that may mimic multiple sclerosis exacerbations*</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Eye disorders</u></em></p><p dir="ltr">Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Retinal vascular disorders (i.e. retinopathy, cotton wool spots, obstruction of retinal artery or vein)*</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Vascular disorders</u></em></p><p dir="ltr">Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thromboembolic events*</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Respiratory, thoracic and mediastinal disorders</u></em></p><p dir="ltr">Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dyspnoea*</p><p dir="ltr">Not known:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pulmonary arterial hypertension* (class label for interferon products, see below Pulmonary arterial hypertension)</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Gastrointestinal disorders</u></em></p><p dir="ltr">Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea, vomiting, nausea</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Skin and subcutaneous tissue disorders</u></em></p><p dir="ltr">Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pruritus, rash, erythematous rash, maculo-papular rash, alopecia*</p><p dir="ltr">Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Urticaria*</p><p dir="ltr">Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Quincke&rsquo;s oedema (angio-oedema) *, erythema multiforme*, erythema multiforme‑like skin reactions*, Stevens Johnson syndrome*</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Musculoskeletal and connective disorders</u></em></p><p dir="ltr">Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Myalgia, arthralgia</p><p dir="ltr">Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Drug-induced lupus erythematosus*</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Renal and urinary disorders</u></em></p><p dir="ltr">Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nephrotic syndrome*, glomerulosclerosis* (see section 4.4)</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>General disorders and administration site conditions</u></em></p><p dir="ltr">Very common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Injection site inflammation, injection site reaction, influenza-like symptoms</p><p dir="ltr">Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Injection site pain, fatigue, rigors, fever</p><p dir="ltr">Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Injection site necrosis, injection site mass, injection site abscess, injection site infections*, increased sweating*</p><p dir="ltr">Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Injection site cellulitis*</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Paediatric population</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">No formal clinical trials or pharmacokinetic studies have been conducted in children or adolescents. Limited safety data suggest that the safety profile in children and adolescents (2 to 17&nbsp;years old) receiving Rebif&nbsp;22&nbsp;micrograms or 44&nbsp;micrograms three&nbsp;times weekly is similar to that seen in adults.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Class effects</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">The administration of interferons has been associated with anorexia, dizziness, anxiety, arrhythmias, vasodilation and palpitation, menorrhagia and metrorrhagia.</p><p dir="ltr">An increased formation of auto‑antibodies may occur during treatment with interferon&nbsp;beta.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Pulmonary arterial hypertension</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Cases of pulmonary arterial hypertension (PAH) have been reported with interferon beta products. Events were reported at various time points including up to several years after starting treatment with interferon beta.</p><p dir="ltr">&nbsp;</p><p dir="ltr">To report any side effect(s):</p><ul dir="ltr"><li><strong><em>Saudi Arabia: </em></strong></li></ul><p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p>- The National Pharmacovigilance Centre (NPC)</p><ul><li>Fax: +966-11-205-7662</li><li>Toll free phone: 8002490000</li><li>E-mail: npc.drug@sfda.gov.sa&nbsp;</li><li>Website: https://ade.sfda.gov.sa/</li></ul><p>&nbsp;</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp; Other GCC States:</p><p dir="ltr">&nbsp;</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">In case of overdose, patients should be hospitalised for observation and appropriate supportive treatment should be given</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Pharmacotherapeutic group: Immunostimulants, Interferons, ATC code: L03AB07</p><p dir="ltr">&nbsp;</p><p dir="ltr">Interferons are a group of endogenous glycoproteins endowed with immunomodulatory, antiviral and antiproliferative properties.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Rebif (interferon&nbsp;beta‑1a) shares the same amino acid sequence with endogenous human interferon&nbsp;beta. It is produced in mammalian cells (Chinese hamster ovary) and is therefore glycosylated like the natural protein.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Regardless of the route of dosing, pronounced pharmacodynamic changes are associated with the administration of Rebif. After a single dose, intracellular and serum activity of 2&rsquo;5&rsquo;OAS&nbsp;synthetase and serum concentrations of beta‑2&nbsp;microglobulin and neopterin increase within 24&nbsp;hours, and start to decline within 2&nbsp;days. Intramuscular and subcutaneous administrations produce fully superimposable responses. After repeated subcutaneous administration every 48&nbsp;hours for 4&nbsp;doses, these biological responses remain elevated, with no signs of tolerance development.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Biological response markers (e.g., 2&rsquo;,5&rsquo;‑OAS activity, neopterin and beta 2‑microglobulin) are induced by interferon beta‑1a following subcutaneous doses administered to healthy volunteer subjects. Time to peak concentrations following a single subcutaneous injection were 24 to 48&nbsp;hours for neopterin, beta‑2-microglobulin and 2&rsquo;5&rsquo;OAS, 12&nbsp;hours for MX1 and 24&nbsp;hours for OAS1 and OAS2 gene expression. Peaks of similar height and time were observed for most of these markers after first and sixth administration.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The precise mechanism of action of Rebif&nbsp;in multiple sclerosis is still under investigation.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Single clinical event suggestive of multiple sclerosis</p><p dir="ltr">&nbsp;</p><p dir="ltr">One 2-year controlled clinical trial with Rebif was performed in patients with a single clinical event suggestive of demyelination due to multiple sclerosis. The patients enrolled into the trial had at least two clinically silent lesions on the T2-weighted MRI scan, with a size of at least 3&nbsp;mm, at least one of which is ovoid or periventricular or infratentorial. Any disease other than multiple sclerosis that could better explain signs and symptoms of the patient had to be excluded.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Patients were randomised in a double-blind manner to either Rebif 44&nbsp;micrograms given three times per week, Rebif 44&nbsp;micrograms once weekly, or placebo. If a second clinical demyelinating event occurred confirming definite multiple sclerosis, patients switched to the recommended posology of Rebif 44&nbsp;micrograms three times per week in an open label manner, while maintaining blinding as to initial randomisation.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Efficacy results of Rebif 44&nbsp;micrograms given three times per week compared to placebo from this study are as follows:</p><p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:619px"><thead><tr><td rowspan="2" style="vertical-align:top"><p><strong>Parameter</strong></p><p>Statistics</p></td><td colspan="3" style="vertical-align:top"><p><strong>Treatment</strong></p></td><td colspan="5" style="vertical-align:top"><p><strong>Treatment Comparison</strong></p><p><strong>Rebif 44 mcg tiw versus Placebo</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Placebo<br />(n=171)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Rebif 44</strong></p><p><strong>mcg tiw*<br />(n=171)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Risk Reduction</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Cox&rsquo;s Proportional Hazard Ratio [95% CI]</strong></p></td><td style="vertical-align:top"><p><strong>Log-Rank</strong></p><p><strong>p-value</strong></p></td></tr></thead><tbody><tr><td colspan="9" style="vertical-align:top"><p><strong>McDonald (2005) Conversion</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of events</p></td><td colspan="2" style="vertical-align:top"><p>144</p></td><td style="vertical-align:top"><p>106</p></td><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p><p>51%</p></td><td colspan="2" rowspan="2" style="vertical-align:top"><p>&nbsp;</p><p>0.49 [0.38;0.64]</p></td><td colspan="2" rowspan="2" style="vertical-align:top"><p>&nbsp;</p><p>&lt;0.001</p></td></tr><tr><td style="vertical-align:top"><p>KM Estimate</p></td><td colspan="2" style="vertical-align:top"><p>85.8%</p></td><td style="vertical-align:top"><p>62.5%</p></td></tr><tr><td colspan="9" style="vertical-align:top"><p><strong>CDMS Conversion</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of events</p></td><td colspan="2" style="vertical-align:top"><p>60</p></td><td style="vertical-align:top"><p>33</p></td><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p><p>52%</p></td><td colspan="2" rowspan="2" style="vertical-align:top"><p>&nbsp;</p><p>0.48 [0.31;0.73]</p></td><td colspan="2" rowspan="2" style="vertical-align:top"><p>&nbsp;</p><p>&lt;0.001</p></td></tr><tr><td style="vertical-align:top"><p>KM Estimate</p></td><td colspan="2" style="vertical-align:top"><p>37.5%</p></td><td style="vertical-align:top"><p>20.6%</p></td></tr><tr><td colspan="9" style="vertical-align:top"><p><strong>Mean CUA Lesions per Subject per Scan During the Double Blind Period</strong></p></td></tr><tr><td style="vertical-align:top"><p>Least Square Means (SE)</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>2.58 (0.30)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.50 (0.06)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>81%</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>0.19 [0.14;0.26]</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>&lt;0.001</p></td></tr><tr><td colspan="9" style="vertical-align:top"><p>* tiw &ndash; three times per week</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr">For the time being there is no well established definition of a high risk patient, although a more conservative approach is to accept at least nine T2 hyperintense lesions on the initial scan and at least one new T2 or one new Gd-enhancing lesion on a follow-up scan taken at least 1 month after the initial scan. In any case, treatment should only be considered for patients classified as high risk.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Relapsing-remitting multiple sclerosis</p><p dir="ltr"><em>&nbsp;</em></p><p dir="ltr">The safety and efficacy of Rebif has been evaluated in patients with relapsing-remitting multiple sclerosis at doses ranging from 11 to 44&nbsp;micrograms (3‑12&nbsp;million&nbsp;IU), administered subcutaneously three&nbsp;times per&nbsp;week. At licensed posology, Rebif&nbsp;44&nbsp;micrograms has been demonstrated to decrease the incidence (approximately&nbsp;30%&nbsp;over 2&nbsp;years) and severity of clinical relapses in patients with at least 2&nbsp;exacerbations in the previous 2&nbsp;years and with an EDSS of 0‑5.0 at entry. The proportion of patients with disability progression, as defined by at least one point increase in EDSS confirmed three&nbsp;months later, was reduced from 39% (placebo) to 27% (Rebif&nbsp;44&nbsp;micrograms). Over 4&nbsp;years, the reduction in the mean exacerbation rate was 22% in patients treated with Rebif&nbsp;22&nbsp;micrograms, and 29% in patients treated with Rebif&nbsp;44&nbsp;micrograms group compared with a group of patients treated with placebo for 2&nbsp;years and then either Rebif&nbsp;22 or Rebif&nbsp;44&nbsp;micrograms for 2&nbsp;years.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Secondary progressive multiple sclerosis</p><p dir="ltr">&nbsp;</p><p dir="ltr">In a 3‑year study in patients with secondary progressive multiple sclerosis (EDSS&nbsp;3‑6.5) with evidence of clinical progression in the preceding two years and who had not experienced relapses in the preceding 8&nbsp;weeks, Rebif had no significant effect on progression of disability, but relapse rate was reduced by approximately&nbsp;30%. If the patient population was divided into 2&nbsp;subgroups (those with and those without relapses in the 2‑year period prior to study entry), there was no effect on disability in patients without relapses, but in patients with relapses, the proportion with progression in disability at the end of the study was reduced from 70% (placebo) to 57% (Rebif&nbsp;22&nbsp;micrograms and 44&nbsp;micrograms combined). These results obtained in a subgroup of patients a&nbsp;posteriori should be interpreted cautiously.</p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">Primary progressive multiple sclerosis</p><p dir="ltr">&nbsp;</p><p dir="ltr">Rebif has not yet been investigated in patients with primary progressive multiple sclerosis, and should not be used in these patients.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Absorption</u></p><p dir="ltr">In healthy volunteers after intravenous administration, interferon&nbsp;beta‑1a exhibits a sharp multi‑exponential decline, with serum levels proportional to the dose. Subcutaneous and intramuscular administrations of Rebif produce equivalent exposure to interferon&nbsp;beta.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Distribution</u></p><p dir="ltr">Following repeated subcutaneous injections of 22&nbsp;and 44&nbsp;micrograms doses of Rebif maximum concentrations were typically observed after 8&nbsp;hours, but this was highly variable.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Elimination</u></p><p dir="ltr">After repeated subcutaneous doses in healthy volunteers, the main PK parameters (AUC<sub>tau</sub> and C<sub>max</sub>) increased proportional to the increased in dose from 22&nbsp;micrograms to 44&nbsp;micrograms. The estimated apparent half-life is 50 to 60&nbsp;hours, which is in line with the accumulation observed after multiple dosing.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Metabolism</u></p><p dir="ltr">Interferon&nbsp;beta‑1a is mainly metabolised and excreted by the liver and the kidneys.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated-dose toxicity, and genotoxicity.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Rebif has not been investigated for carcinogenicity.</p><p dir="ltr">&nbsp;</p><p dir="ltr">A study on embryo/foetal toxicity in monkeys showed no evidence of reproductive disturbances. An increased risk of abortions has been reported in animal studies of other alpha and beta interferons. No information is available on the effects of the interferon&nbsp;beta‑1a on male fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Mannitol 22.50 mg</p><p dir="ltr">Poloxamer&nbsp;0.25 mg</p><p dir="ltr">L‑methionine 0.06 mg</p><p dir="ltr">Benzyl alcohol 2.50 mg</p><p dir="ltr">Sodium acetate 0.50 ml</p><p dir="ltr">Acetic acid for pH adjustment</p><p dir="ltr">Sodium hydroxide for pH adjustment</p><p dir="ltr">Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Store in a refrigerator (2&deg;C&nbsp;&ndash;&nbsp;8&deg;C) away from the cooling element. Do not freeze. Store in the original package in order to protect from light.</p><p dir="ltr">&nbsp;</p><p dir="ltr">For the purpose of ambulatory use, the patient may remove Rebif from the refrigerator and store it not above 25&deg;C for one single period of up to 14&nbsp;days. Rebif must then be returned to the refrigerator and used before the expiry date.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">One&nbsp;mL type&nbsp;1 glass syringe, with a stainless-steel needle, containing 0.5&nbsp;mL solution.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Rebif&nbsp;44&nbsp;micrograms is available as a package of 1,&nbsp;3, 12, or 36&nbsp;syringes.</p><p dir="ltr">Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">The solution for injection in a pre‑filled syringe is ready for use. It may also be administered with a suitable auto‑injector.</p><p dir="ltr">&nbsp;</p><p dir="ltr">For single use only. Only clear to opalescent solution without particles and without visible signs of deterioration should be used.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Merck Serono SA 
Zone industrielle de l'Ouriettaz 
1170 Aubonne 
 Switzerland

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                03 March 2020 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>